Navigation Links
Biotech firm has strokes, Alzheimer's in its sights

Madison, Wis. - While much of the attention paid to Quincy Bioscience centers on the compound it is developing from jellyfish, it is the company's emerging business model that may put other medical treatments 25,000 leagues under the sea.

Quincy Bioscience is based in Madison's University Research Park, but it derives its research supp......

Full article >>> ept/Psychology/faculty/moyer.html">James Moyer, said lab results thus far indicate the protein, aequorin, is much more "neuroprotective" than existing treatments. According to Underwood, aequorin has helped anywhere from 28 to 45 percent of brain cells survive, without toxicity, after being subjected to the lab equivalent of a stroke.

Ninety-nine percent of the body's calcium is conta......

Full article >>> sing the role future funding will play.

The company expects to have a pharmaceutical product on the market in seven years. It will seek to raise private equity to develop aequorin-based therapies for each disease it targets, starting with strokes and followed (not necessarily in this order) by Alzheimer's, Parkinson's, Huntington's, and Amyotrophic Lateral Sclerosis (ALS), also known as ......

Full article >>> property portfolio.

IQ visions

Quincy's science and the business model may take it farther than most biotechs, but it's the Milwaukee-Madison connection that intrigues Leonhart and others that envision a robust IQ Corridor. "It kind of shows that the research in this state can be created anywhere and be successfully planted elsewhere," he said.

......

Full article >>>
'"/>

Source:wistechnology.com By Joe Vanden Plas 08/31/06


Related biology technology :

1. Biotech officials praise focus of new venture fund
2. Biotech executive books a career flight thats closer to home
3. Gala Biotech among companies sold for $3.3 billion
4. Biotech with Madison ties raises $21M in capital
5. Biotech firm uses live heart tissue in drug screens
6. Biotech talent drew venture-funded firm to Madison
7. 42 days until the 2006 Olympics of Biotechnology in Chicago
8. Biotech crops gaining acceptance, but their full promise has yet to be fulfilled
9. Biotech leads list of top U.S. companies to work for
10. Biotech flourishes in 2005 while Big Pharma is on the decline
11. Though Weakening, Biotech IPO Market Still Viable, Burril & Co. Says
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/27/2017)... HAMILTON, Bermuda , Feb. 27, ... ADXS ) and SELLAS Life Sciences ... developing cancer immunotherapies, today announced that Advaxis has ... cancer immunotherapy agent using Advaxis, proprietary Lm ... targeted heteroclitic peptide antigen mixture (galinpepimut-S). ...
(Date:2/25/2017)... ... February 25, 2017 , ... The STARR Coalition ... effort to create meaningful change by increasing communication, partnerships and goodwill among stakeholders ... and patients’ mental health well-being. , Both organizations are dedicated to promoting patient ...
(Date:2/24/2017)... , Feb. 24, 2017  Aethlon Medical, Inc. (Nasdaq: ... authored by its Chairman and CEO, Jim Joyce ... Munich Security Conference last Saturday, Bill Gates ... kill more people than nuclear weapons. Mr. Gates expressed ... U.K. intelligence agencies, that scientific terrorists have access to ...
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the ... today announced its financial results for the fourth quarter and ... Financial Highlights Total sales in the ... or increased by 13.6% in USD terms to $77.6 million ... Gross profit increased by 13.3% to $46.8 million ...
Breaking Biology Technology:
(Date:2/7/2017)... York , February 7, 2017 ... ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the ... and electronic transaction processing services, is pleased to announce ... the Company. Effective January 31, 2017, ... Board of Directors, CEO and President.  An experienced payment ...
(Date:2/3/2017)... -- Texas Biomedical Research Institute announced that its Board of Trustees ... the Institute,s new President and CEO. Dr. Schlesinger will take ... is currently the Chair of the Department of Microbial Infection ... Biology at Ohio State University. "We are delighted ... of Texas Biomed," said Dr. James O. Rubin , ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
Breaking Biology News(10 mins):